Latest From Ian Haydock
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
First-in-class ADC set for expanded use on the back of additional data, but analysts see first-line setting as probably the main growth driver.
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things.